STV News visited our premises on Wednesday 2nd August to discuss NovaBiotics’ recently published work, describing how the novel antimicrobial peptide Luminaderm (NP108, derived from NovaBiotics proprietary peptide drug discovery platform) is highly effective in vitro against drug sensitive & drug resistant Staphylococcus aureus (MRSA & MSSA).

The report featured on the news bulletins that day and an excerpt can be viewed below